Quintrio
Home

Stock overview

Alcon Inc. Ordinary Shares

ALC

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Last trade $74.34
Day change +$0.70 (+0.95%)
Day range $72.39 – $74.38
Volume 1,304,924
Market cap $35.38B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$35.38B
Price / earnings
80.4×
Price / book
1.81×
Price / sales
4.12×
EV / sales
4.47×
EV / EBITDA
36.01×

Profitability

Earnings per share
$0.92
Return on assets
1.59%
Return on equity
2.25%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.2×
Current ratio
2.16×
Quick ratio
1.31×
Cash ratio
0.44×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
—

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ALC, quarterly periods
Line itemQ2 FY2022 Jun 30, 2022Q4 FY2021 Dec 31, 2021Q3 FY2021 Sep 30, 2021Q2 FY2021 Jun 30, 2021Q1 FY2021 Mar 31, 2021Q4 FY2020 Dec 31, 2020Q3 FY2020 Sep 30, 2020Q2 FY2020 Jun 30, 2020
Revenue$2.22B$2.15B$2.1B$2.11B$1.93B$1.94B$1.84B$1.21B
Cost of revenue$1.01B$943M$907M$890M$899M$1.07B$990M$869M
Gross profit$1.2B$1.21B$1.2B$1.22B$1.03B$875M$848M$345M
Selling, general and administrative$803M$813M$779M$785M$699M$737M$685M$595M
Research and development$181M$180M$318M$178M$166M$155M$216M$163M
Total operating expenses$1B$1.02B$1.18B$991M$882M$734M$977M$811M
Operating income$200M$182M$20M$229M$149M$141M-$129M-$466M
Interest expense-$31M-$28M-$31M-$30M-$31M-$31M-$32M-$30M
Income before taxes$147M$141M-$23M$191M$109M$104M-$168M-$502M
Income taxes-$1M$2M-$25M$40M$25M$9M-$21M-$80M
Net income$148M$139M$2M$151M$84M$95M-$147M-$422M
Net income attributable to common shareholders$148M$139M$2M$151M$84M$95M-$147M-$422M
EBITDA$200M$182M$453M$229M$433M$141M$301M-$67M
Basic earnings per share$0.30$0.29$0.00$0.31$0.17$0.19-$0.30-$0.86
Diluted earnings per share$0.30$0.28$0.00$0.31$0.17$0.19-$0.30-$0.86

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Alcon: 3 Key Takeaways for Long-Term Investors

Alcon reported Q3 2026 earnings with ~6% full-year net sales growth guidance and double-digit core EPS growth. The company is defending its premium intraocular lens market share against competitors through new products (Vivity Pro, TruPlus), expanding UNITY surgical equipment placements to 40% of U.S. teaching hospitals, and acquiring Neurotech Pharmaceuticals for retinal disease treatment with peak sales potential of $250-400 million. Management emphasized outpacing the 3% baseline eye care market growth through operational efficiency and margin expansion.

Zacks Investment Research

ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down

Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.

Zacks Investment Research

Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say

Alcon reported $2.72 billion in revenue for Q3 2026, up 4.9% year-over-year, slightly missing the consensus estimate of $2.73 billion. EPS of $0.91 exceeded expectations of $0.89. The company showed strong growth in Vision Care (+5.8%) and Equipment/other segments (+10.7%), but faced headwinds in Implantables (-2.3%) and Other revenues (-20%). The stock has outperformed the broader market with a +16.8% return over the past month.

Zacks Investment Research

Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?

Alcon (ALC) shares surged 6.8% to $77.31 on investor optimism ahead of its third quarter 2026 earnings release on November 11. The company is expected to report EPS of $0.89 (up 12.7% YoY) and revenues of $2.73 billion (up 5.6% YoY). However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock may struggle to maintain momentum without further positive estimate revisions. NeuroPace (NPCE), a peer in the medical instruments industry, also gained 8.4% but remains down 2.8% over the past month.

GlobeNewswire Inc.

Wellcome Leap Appoints John Young and Thomas Glanzmann to Board of Directors

Wellcome Leap, a nonprofit founded by the Wellcome Trust to accelerate health breakthroughs, announced that John Young (former Pfizer Chief Business Officer) and Thomas Glanzmann (former Grifols CEO) have joined its Board of Directors. Both bring decades of experience in global healthcare leadership, pharmaceutical operations, and business development.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
May 6, 2026CHF 0.28May 7, 2026recurring
May 14, 2025CHF 0.28May 15, 2025recurring
May 14, 2024CHF 0.24May 16, 2024recurring
May 10, 2023CHF 0.21May 12, 2023recurring
May 3, 2022CHF 0.20May 5, 2022recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.